Literature DB >> 7814280

Ivermectin in human medicine.

E A Ottesen1, W C Campbell.   

Abstract

Ivermectin is a potent macro-cyclic lactone causing paralysis in many nematodes and arthropods through an influx of chloride ions across cell membranes. It is currently the drug of choice for human onchocerciasis and shows potent microfilaricidal activity against the other major filarial parasites of human (Wuchereria bancrofti, Brugia malayi, Loa loa and Mansonella ozzardi) but not against M. perstans. Whether or not it also kills the adult-stage of these parasites is currently under study. Ivermectin also has excellent efficacy in both human strongyloidiasis and cutaneous larva migrans for which good alternative treatments have not been available; and it is as effective as currently available drugs against the intestinal nematodes Ascaris lumbricoides, Trichuris trichiura and Enterobius vermicularis; against the human hookworms it shows only partial efficacy. Preliminary studies indicate that ivermectin has the potential to become the drug of choice for ectoparasitic infestations (mites, lice) of humans as well.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7814280     DOI: 10.1093/jac/34.2.195

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  31 in total

Review 1.  Nontraditional microbial bioactive metabolites.

Authors:  V Bĕhal
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

2.  Phase III Clinical Trial to Evaluate Ivermectin in the Reduction of Mansonella ozzardi infection in the Brazilian Amazon.

Authors:  Sergio de Almeida Basano; Juliana de Souza Almeida Aranha Camargo; Gilberto Fontes; Antonieta Relvas Pereira; Jansen Fernandes Medeiros; Mayara Costa de Oliveira Laudisse; Ricardo de Godoi Mattos Ferreira; Luís Marcelo Aranha Camargo
Journal:  Am J Trop Med Hyg       Date:  2018-01-04       Impact factor: 2.345

Review 3.  The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.

Authors:  Mandy Juarez; Alejandro Schcolnik-Cabrera; Alfonso Dueñas-Gonzalez
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

4.  Probability risk transmission matrix as a decision tool for assessing methods of transmission interruption of Wuchereria bancrofti infection.

Authors:  P K DAS; P Vanamail
Journal:  Epidemiol Infect       Date:  2007-06-20       Impact factor: 2.451

5.  Sustained clearance of Mansonella ozzardi infection after treatment with ivermectin in the Brazilian Amazon.

Authors:  Sergio de Almeida Basano; Gilberto Fontes; Jansen Fernandes Medeiros; Juliana Souza de Almeida Aranha Camargo; Luana Janaína Souza Vera; Marcos Paulo Parente Araújo; Maira Santiago Pires Parente; Ricardo de Godoi Mattos Ferreira; Pedro di Tárique Barreto Crispim; Luís Marcelo Aranha Camargo
Journal:  Am J Trop Med Hyg       Date:  2014-04-07       Impact factor: 2.345

Review 6.  Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders.

Authors:  Sheraz Khoja; Nhat Huynh; Alicia M P Warnecke; Liana Asatryan; Michael W Jakowec; Daryl L Davies
Journal:  Psychopharmacology (Berl)       Date:  2018-03-02       Impact factor: 4.530

7.  Endogenous Voltage Potentials and the Microenvironment: Bioelectric Signals that Reveal, Induce and Normalize Cancer.

Authors:  Brook Chernet; Michael Levin
Journal:  J Clin Exp Oncol       Date:  2013

Review 8.  Anthelmintics. A comparative review of their clinical pharmacology.

Authors:  N de Silva; H Guyatt; D Bundy
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

9.  A BRIEF REVIEW ON THE MODE OF ACTION OF ANTINEMATODAL DRUGS.

Authors:  Melanie Abongwa; Richard J Martin; Alan P Robertson
Journal:  Acta Vet (Beogr)       Date:  2017-06-26       Impact factor: 0.800

10.  Efficacy of different treatment regimes against setariosis (Setaria tundra, Nematoda: Filarioidea) and associated peritonitis in reindeer.

Authors:  Sauli Laaksonen; Antti Oksanen; Toomas Orro; Harri Norberg; Mauri Nieminen; Antti Sukura
Journal:  Acta Vet Scand       Date:  2008-12-16       Impact factor: 1.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.